References
- World Health OrganizationAdherence to long-term therapies Evidence for actionGeneva, SwitzerlandWorld Health Organization2003
- GlezenWPTaberLHFrankALKaselJARisk of primary infection and reinfection with respiratory syncytial virusAm J Dis Child198614065435463706232
- LawBJCarbonell-EstranyXSimoesEAAn update on respiratory syncytial virus epidemiology: a developed country perspectiveRespir Med200296Suppl BS1S711996399
- Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study GroupPediatrics1998102(3 Pt 1):531537
- GreenoughACoxSAlexanderJHealth care utilisation of infants with chronic lung disease, related to hospitalisation for RSV infectionArch Dis Child200185646346811719328
- SampalisJSMorbidity and mortality after RSV-associated hospitalizations among premature Canadian infantsJ Pediatr2003143Suppl 5S150S15614615714
- PelletierAJMansbachJMCamargoCAJrDirect medical costs of bronchiolitis hospitalizations in the United StatesPediatrics200611862418242317142527
- American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infectionsPediatrics20031126 Pt 11442144614654627
- Canadian Paediatric SocietyPalivizumab and respiratory syncytial virus globulin intravenous for the prophylaxis of respiratory syncytial virus infection in high risk infants. Infectious Diseases and Immunization Committee and Fetus and Newborn CommitteePaediatr Child Health199944744480
- RobbinsJMTilfordJMGillaspySRParental emotional and time costs predict compliance with respiratory syncytial virus prophylaxisAmbul Pediatr20022644444812437390
- BrachtMHefferMO’BrienKDevelopment, implementation, and evaluation of a community- and hospital-based respiratory syncytial virus prophylaxis programAdv Neonatal Care200551394915685161
- GolombekSGBerningFLagammaEFCompliance with prophylaxis for respiratory syncytial virus infection in a home settingPediatr Infect Dis J200423431832215071285
- PaulDALeefKHChidekelAHome delivery of palivizumab: outcomes and compliance in regional preterm infantsDel Med J2002741111511838265
- LangkampDLHlavinSMFactors predicting compliance with palivizumab in high-risk infantsAm J Perinatol200118634535211607852
- PignottiMSCatarziSDonzelliGA 4-year survey on palivizumab respiratory syncytial virus (RSV)-prophylaxis: how can compliance be improved?J Matern Fetal Neonatal Med200619422122416854695
- SingletonRJBrudenDBrooksLCloser to home: local care improves compliance with RSV prophylaxis in high-risk infantsInt J Circumpolar Health20066514716544642
- OhPILanctôtKLYoonAPalivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomesPediatr Infect Dis J200221651251812182374